跳至主要内容
临床试验/NL-OMON52940
NL-OMON52940招募中3 期

Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy (ENFORCE) - ENFORCE

Canisius Wilhelmina Ziekenhuis0 个研究点目标入组 140 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Signed informed consent form 1 (IC)
  • 2. Age > 18 years
  • 3. Histologically confirmed prostate cancer
  • 4. Scheduled for RP as primary treatment with at least one-side nervesparing.
  • 5. Non-metastatic disease (cN0M0)
  • 6. Willing to provide blood samples to determine testosterone level
  • 7. Signed informed consent form 2 (ICF)
  • 8. Undetectable PSA level at 4-week follow-up
  • 9. Willing to use testosterone gel or placebo gel
  • 10. a minimal score of 40 points for the EPIC-26 sexual domain.

排除标准

  • 1. Any previous treatment for prostate cancer, for example but not limited to:
  • anti-hormonal therapy, radiotherapy, brachytherapy (active surveillance is
  • 2. Previous use of TRT for any reason
  • 3. History of male breast cancer
  • 4. History of liver tumor
  • 5. Uncontrolled hypertension
  • 6. Allergy for components in the testosterone therapy agent or placebo
  • 7. Use of vitamin-K antagonists (acenocoumarol or fenprocoumon)
  • 8. pT3b or pT4
  • 9. Positive surgical margin (PSM) and ISUP 4 or 5 (ISUP 1 to 3 with PSM and
  • ISUP 4 or 5 without PSM can be included).
  • 10. Metastatic lymph nodes if a PLND has been done
  • 11. BMI > 30

研究者

发起方
Canisius Wilhelmina Ziekenhuis

相似试验